| 1 |
NCT00342173 |
Completed |
Costa Rican Natural History Study of HPV and Cervical Neoplasia |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Natural History of human papillomaviruses (HPV) and cervical neoplasia
|
11545 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT00342173 |
999999030
OH99-C-N030 |
|
May 20, 1999 |
|
|
June 21, 2006 |
April 5, 2018 |
|
- Costa Rican Social Security Administration
Tres Rios, Costa Rica
|
| 2 |
NCT03309033 |
Not yet recruiting |
Fifteen-Year Immunologic Follow-Up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the Costa Rica HPV-16/18 Vaccine Trial (CVT) the CVT EXTEND Study |
- Human Papillomavirus
- Cervical Cancer
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Estimate the change in antibody levels between years 10 and 15 foreach dose regimen (i.e. 1-dose, 2-doses, 3-doses) and each HPV type (i.e. 16, 18).
- Estimate the proportion of individuals who become seronegative (i.e.: serorevert) between years 10 and 15 for each dose regimen (i.e. 1-dose, 2-doses, 3-doses) and each HPV type (i.e. 16, 18).
|
1000 |
Female |
30 Years to 38 Years (Adult) |
NCT03309033 |
999917173
17-C-N173 |
|
April 25, 2018 |
December 31, 2022 |
December 31, 2022 |
October 13, 2017 |
April 20, 2018 |
|
- Agencia Costarricen se de Investigacio nes Biom(SqrRoot)(Copyright)dicas (ACIB)
Liberia, Costa Rica
|
| 3 |
NCT00128661 |
Completed
Has Results |
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants |
- Cervical Cancer
- Precancerous Condition
|
- Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
- Biological: hepatitis A inactivated virus vaccine
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.
- Number of Cervical Infection With HPV16 or HPV18.
- Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type
- (and 12 more...)
|
7466 |
Female |
18 Years to 25 Years (Adult) |
NCT00128661 |
CDR0000441189
NCI-04-C-N191
NCI-590299/009
GSK-590299/009 |
|
June 2004 |
December 2010 |
December 2010 |
August 10, 2005 |
June 1, 2012 |
May 2, 2012 |
- Proyecto Epidemiologico Guanacaste
Liberia, Costa Rica
|
| 4 |
NCT00867464 |
Active, not recruiting |
Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls |
- Cervical Cancer
- Human Papillomavirus
- Anal Cancer
- Oral Cancer
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 10-year global impact of HPV-16/18 vaccination of young adultwomen
- Determinants of the immune response to HPV and the vaccine, andmarkers of long-term protection
- The natural history of HPV and cervical disease in vaccinated andunvaccinated populations
|
8670 |
Female |
24 Years to 32 Years (Adult) |
NCT00867464 |
999909106
09-C-N106 |
|
March 19, 2009 |
|
|
March 23, 2009 |
April 5, 2018 |
|
- Proyecto Epidemiologico Guanacasate
Liberia, Costa Rica
|
| 5 |
NCT03179306 |
Active, not recruiting |
Cervix Image Sharing Protocol (CISP) |
- Cervical Cancer
- Cervical Abnormalities
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cervical intraepithelial neoplasia grade 3 (CIN3) or worse.
|
27084 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT03179306 |
999917098
17-C-N098 |
|
May 15, 2017 |
March 2, 2022 |
March 2, 2022 |
June 7, 2017 |
April 5, 2018 |
|
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
|
| 6 |
NCT03180034 |
Recruiting |
Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines |
- Cervical Cancer
- Cervical HPV Infection
- Anti-HPV Antibody Patterns
|
- Biological: Cervarix
- Biological: Gardasil 9
|
Interventional |
Phase 4 |
- National Cancer Institute (NCI)
- Bill and Melinda Gates Foundation
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Evaluate non-inferiority of one compared to two vaccination doses of Cervarix in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination
- Evaluate non-inferiority of one compared to two vaccination doses of Gardasil 9 in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination.
- Evaluate one dose of Cervarix compared to no vaccination in the protection against HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination.
- (and 7 more...)
|
25000 |
Female |
12 Years to 20 Years (Child, Adult) |
NCT03180034 |
999917108
17-C-N108 |
|
April 25, 2018 |
December 31, 2022 |
December 31, 2024 |
June 8, 2017 |
April 20, 2018 |
|
- Agencia Costarricense de Investigaciones Biomedicas (ACIB)
Liberia, Costa Rica
|
Create an RSS feed from your search for:
Download the search results for: